Japan approves AstraZeneca’s Soliris for paediatric patients with gMG

Betsy Goodfellow | August 24, 2023 | News story | Medical Communications AstraZeneca, MHLW, Musculo-skeletal disorder, gMG, paediatric, soliris 

AstraZeneca has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Soliris (eculizumab) for the extended use of treating generalised myasthenia gravis (gMG) in paediatric patients who are anti-acetylocholine receptor (AChR) antibody-positive and whose symptoms are difficult to control with other treatments.

This drug is the first to be approved in Japan for the treatment of children and adolescents with gMG, with approval following results from phase 3 of the drug trial. This trial demonstrated clinical benefit in indicating this in patients who previously failed immunosuppressive treatment.

Keiko Ishigaki, MD PhD, department of Pediatrics at Tokyo Women’s Medical University, School of Medicine, Japan, commented: “gMG is challenging to manage in paediatric patients, as current therapies available to this population, such as immunosuppressants, may not offer adequate control as the disease progresses. Today’s expanded approval of Soliris in Japan demonstrates the impact of C5 complement inhibition in treating gMG, offering paediatric patients a targeted option with the potential to preserve muscle function and reduce disease severity.”

Marc Dunoyer, CEO of Alexion, a subsidiary of AstraZeneca, added: “Paediatric patients living with gMG can become nonresponsive to standard treatments and continue to experience symptoms that impact their mobility, speech and breathing. Our first-in-class C5 inhibitor Soliris has the potential to improve outcomes and quality of life for paediatric patients and their families, and we take pride in delivering this first and only targeted therapy to the paediatric gMG community in Japan.”   

Betsy Goodfellow

Related Content

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, …

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase …

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of …

Latest content